Recent Updates
Recently added Catalysts
ICU Positive Sentiment

SeaStar Medical to Present at the Virtual Emerging Growth Conference on June 12, 2024

Key Takeaway: SeaStar Medical Holding Corporation, a medical device company focused on reducing hyperinflammation, announced that CEO Eric Schlorff will present at the Virtual Emerging Growth Conference on June 12, 2024. During the conference, he will discuss the company and its Selective Cytopheretic Device (SCD). Investors are encouraged to submit questions for the event, which will also be archived online afterward. The company’s developments aim to improve outcomes for critically ill patients, though risks related to regulatory approval and capital funding remain.
Price reaction · baseline $88.5 (2024-06-05 close) · hit after-hours · 2 other ICU headline(s) in the window, move may be shared
day 0 close
-39.4%
day 1
-38%
day 3 · peak
-52.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation at a prominent virtual event highlights company visibility.
  • CEO will share updates on innovative technology, potentially attracting investor interest.
  • Company is focused on developing life-saving solutions for critically ill patients.

CONCERNS & RISKS

  • Forward-looking statements carry inherent risks regarding product approval.
  • Challenges in raising sufficient capital for operations and trials may hinder progress.
  • Potential delays in commercialization could affect market entry.

Full Press Release Details

DENVER, June 06, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that Eric Schlorff, CEO, will hold a fireside chat at the Virtual Emerging Growth Conference on Wednesday, June 12 at 12:35 p.m. Eastern time (9:35 a.m. Pacific time).
During the fireside chat, Mr. Schlorff will provide an overview of SeaStar Medical and the Selective Cytopheretic Device (SCD), and discuss Company updates. Investors can submit questions in advance of the event at Questions@EmergingGrowth.com.
Investors can register to attend the live event here. An archive webcast of the fireside chat will be available approximately 48 hours following the event on the SeaStar Medical website.
About SeaStar Medical
SeaStar Medical is a commercial-stage medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit www.seastarmedical.com or visit us on LinkedIn or X.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1955. These forward-looking statements include, without limitation, SeaStar Medical’s expectations with respect to the ability of SCD to treat patients with AKI and other diseases; the expected regulatory approval process and timeline for commercialization; and the ability of SeaStar Medical to meet the expected timeline. Words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside SeaStar Medical’s control and are difficult to predict. Factors that may cause actual future events to differ materially from the expected results include, but are not limited to: (i) the risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates; (ii) the risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials; (iii) the risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators, (iv) the risk that SeaStar Medical may never achieve or sustain profitability; (v) the risk that SeaStar Medical may not be able to access funding under existing agreements; (vi) the risk that third-parties suppliers and manufacturers are not able to fully and timely meet their obligations, (vii) the risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical’s products and services, (viii) the risk that SeaStar Medical is unable to secure or protect its intellectual property, and (ix) other risks and uncertainties indicated from time to time in SeaStar Medical’s Annual Report on Form 10-K, including those under the “Risk Factors” section therein and in SeaStar Medical’s other filings with the SEC. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SeaStar Medical assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
SeaStar Medical Contact:

Frequently Asked Questions

What is the focus of SeaStar Medical Corporation?

SeaStar Medical is focused on developing solutions to mitigate hyperinflammation effects on vital organs.

When is the fireside chat with SeaStar’s CEO scheduled?

The fireside chat is scheduled for June 12 at 12:35 p.m. Eastern time.

How can investors submit questions for the event?

Investors can submit questions in advance via email at Questions@EmergingGrowth.com.

Where can I find the webcast after the event?

An archive of the webcast will be available on the SeaStar Medical website 48 hours post-event.

What does the Selective Cytopheretic Device target?

The Selective Cytopheretic Device targets effector cells that drive systemic inflammation.

Last updated: Jun 6, 2024